Compare Neurocrine Biosciences Inc (NBIX) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Newegg Commerce Inc — how do they compare? Neurocrine Biosciences Inc trades at $142.6 (market cap $14.36B), while Newegg Commerce Inc trades at $11.72 (market cap $243.30M). The key difference: Neurocrine Biosciences Inc is far larger — about 59× Newegg Commerce Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Newegg Commerce Inc for 14 Days on average.
| NBIX | NEGG | |
|---|---|---|
Market Cap | $14.36B | $243.30M |
Volume | 1,237,180 | 41,252 |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $92.74 |
52-Week Low | $123.10 | $11.49 |
Typical Hold Time | 23 Days | 14 Days |
Enterprise Value | $14.37B | $213.53M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
NEGG trades at $11.69, down 2.66% today, with a bearish technical signal from moving averages but oversold RSI readings. The company shows improving fundamentals with revenue stabilizing around $1.4B and net losses narrowing significantly from -$59M in 2023 to -$4.88M in 2025. Recent earnings beats and strategic partnerships with Western Digital and HPE highlight operational progress, though negative operating cash flow and insider selling present concerns.
The outlook remains mixed with improving profitability trends but significant execution risks. Valuation appears reasonable with P/S of 0.18x, but analyst consensus target of $7.75 suggests 34% downside. Key risks include competitive e-commerce pressures and the need to sustain recent operational improvements amid challenging market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
